SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NexStar Pharm(NXTR) -- Ignore unavailable to you. Want to Upgrade?


To: Miljenko Zuanic who wrote (315)2/10/1999 8:23:00 PM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 328
 
From LIPO 4Q results:

<<International sales during the fourth quarter of 1998 increased by $0.7 million or 19%, primarily due to strong growth in the United Kingdom and Canada versus the comparable prior period. Worldwide unit sales of ABELCET® in the fourth quarter exceeded the comparable prior year period by 38%.>>

So, where are strong penetration on major oncology market in EU: Spain, Germany, France, Italy...???

Miljenko